The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Hicks, David G ^a   Janarthanan, Bagi R ^a   Vardarajan, Ramya ^a   Kulkarni, Swati A ^a   Khoury, Thaer ^a   Dim, Daniel ^a   Budd, G T ^b   Yoder, Brian J ^b   Tubbs, Raymond ^b   Schreeder, Marshall T ^c   Estopinal, Noel C ^c   Beck, Rodney A ^d   Wang, Yanling ^e   Ring, Brian Z ^e   Seitz, Robert S ^d   Ross, Douglas T ^e  

^a UNIVERSITY OF ROCHESTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Clearview Cancer Institute   (United States)

^d Clarient Inc   (United States)

^e Clarient Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRMT2A PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; TRANSFER RNA METHYLTRANSFERASE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR VOLUME; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; ENZYMOLOGY; FEMALE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RISK FACTORS; TRNA METHYLTRANSFERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77952286059     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-108     Document Type: Article

References (20)

1. Arnedos M, Seidman AD. Emerging targeted therapies for breast cancer. Hematol Oncol Clin North Am 2007, 21:321-40. 10.1016/j.hoc.2007.03.005, 17512452.
2. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002, 20:3095-105.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-82. 10.1126/science.3798106, 3798106.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-12. 10.1126/science.2470152, 2470152.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-84. 10.1056/NEJMoa052122, 16236738.
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36. 10.1016/S0140-6736(07)60028-2, 17208639.
7. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-48.
8. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed paclitaxel by, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-9. 10.1200/JCO.2005.02.4091, 16258083.
9. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-33. 10.1200/JCO.2007.11.0106, 17687157.
10. Perou CM, Sorlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-52. 10.1038/35021093, 10963602.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-74. 10.1073/pnas.191367098, 58566, 11553815.
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-23. 10.1073/pnas.0932692100, 166244, 12829800.
13. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-60. 10.1200/JCO.2005.03.3845, 16145060.
14. Ciocca DR, Gago FE, Fanelli MA, Calderwood SK. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol 2006, 102:32-40. 10.1016/j.jsbmb.2006.09.008, 17049840.
15. Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005, 6:247-52. 10.3816/CBC.2005.n.027, 16137436.
16. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3039-47. 10.1200/JCO.2006.05.6564, 16809728.
17. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000. 10.1091/mbc.02-02-0030., 117619, 12058064.
18. Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K, Marr J, Laskey RA, Coleman N. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998, 95:14932-7. 10.1073/pnas.95.25.14932, 24553, 9843993.
19. Di Matteo G, Salerno M, Guarguaglini G, Di Fiore B, Palitti F, Lavia P. Interactions with single-stranded and double-stranded DNA-binding factors and alternative promoter conformation upon transcriptional activation of the Htf9-a/RanBP1 and Htf9-c genes. J Biol Chem 1998, 273:495-505. 10.1074/jbc.273.1.495, 9417108.
20. Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 2008, 14:6602-9. 10.1158/1078-0432.CCR-08-0647, 2722068, 18927301.